Montana’s experimental treatment centers: what the rules require

How much freedom should people have to try a treatment while its benefits and risks are still being studied? Montana has approached that question by creating a state licensing system for experimental treatment centers. Its patient criteria are broader than those of federal right to try, and its rules set out responsibilities for reviewing treatments, informing patients and following what happens afterward. [1] [2]

The development matters to anyone following the future of medicine. It is an effort to widen access while building oversight around it. To understand what it means for an individual, it helps to follow the path from a law to a proposed treatment.

What a center must have in place

Montana’s 2025 law created the licensing category. Implementing rules took effect on July 25, 2026, covering staffing, medical leadership, patient agreements, records, review boards and emergency procedures. [1] [2]

A center must complete licensing requirements, including document review and an on-site inspection, before admitting patients. It also needs the required treatment review board and its evaluation before treatment begins. An application or a planned opening is therefore an early step, not evidence that a service is ready. [7] [2]

The state’s September 1, 2026 report recorded no licensed centers at that time. Anyone considering a later offer should check the provider’s current license directly. [4]

Who can be considered?

The state’s patient criteria do not require a terminal diagnosis. They require consideration of other FDA-approved treatment options, a recommendation from the treating provider, informed consent and documentation that the requirements are met. [3]

The consent discussion must address approved options relevant to the person’s condition or desired health outcome. Patient and provider must agree that conventionally recognized treatments are unlikely to achieve that outcome or are impractically available. The rules require evaluating alternatives; they should not be read as requiring every alternative to have been tried first. [8] [2]

This puts a clinical conversation at the center of eligibility. A signature and willingness to pay are only part of the picture. Nor can an eligible person require a manufacturer or provider to supply a treatment. [9]

The treatment has to qualify too

The statutory definition includes investigational drugs, biological products, devices and other interventions that have successfully completed phase 1 but lack FDA approval for general use. They must also remain in a qualifying clinical investigation or have the documented safety record specified through a qualified medical institution. [10]

Those conditions concern the actual intervention being proposed. An encouraging animal experiment or a study of another company’s product cannot supply the missing development history. Phase 1 is an early stage, usually focused on dose and initial safety; larger and longer studies are needed to establish benefits and detect less common harms. [18]

Who reviews the decision?

The state rules require an experimental treatment review board with at least five members, including a Montana-licensed physician, a researcher experienced in clinical outcomes and an ethicist. Members must be free of the specified conflicts of interest in the centers they review. [2]

The board examines treatment plans, informed consent, alternatives, risks and benefits. It also reviews outcomes and adverse events. It must meet at least monthly and produce a public summary at least annually. These duties make the quality of the board’s work important to the quality of the system.

For a patient, useful questions include: who reviewed this particular treatment, what evidence did they use, and what would make them change or stop it? State board review also needs to be distinguished from any separate ethics or regulatory review required under federal rules.

Consent includes the difficult possibilities

A good consent conversation explains the hoped-for benefit, the most likely outcome and what could go wrong. Montana’s requirements include these possibilities, while the center’s signed patient agreement must explain treatment, costs, payment arrangements, complaints and the relevant statutory liability protection. [8] [2]

Centers must have arrangements for transfer to a local hospital. Serious adverse events must be reported to the state within five days. These requirements make emergency planning and follow-up part of the offer, rather than something left until a problem occurs. [2]

Insurance deserves separate attention. The statute does not require coverage of experimental treatment or resulting care. It also gives specified actors liability protection when its conditions are met. Before signing, patients need to understand their potential costs and obtain advice on legal terms they do not understand. [12] [13]

A contribution toward access

Licensed centers must allocate 2% of net annual profits toward access for qualifying Montana residents. They can provide qualifying free experimental treatment or contribute to an account supporting eligible residents’ health-insurance premiums. The requirement is based on profit, rather than every treatment bill, and it does not guarantee free experimental care for every resident. [14] [15]

How state and federal rules fit together

A Montana license is not FDA marketing approval. Federal right to try retains its own narrower patient and product criteria, and other federal requirements may apply to how an intervention is obtained, distributed and administered. A provider should be able to explain the legal basis for the exact proposal. [16] [17]

The state also permits some treatment outside a center under defined conditions, including board review of risk and a written physician agreement. That provision is not general permission to ship any experimental product across state lines. Product-specific legal questions still need product-specific answers. [2]

What will show whether this works well?

At Healthy Longevity Clinic, our approach to evaluating treatment evidence begins with a practical question: does this intervention help comparable people achieve a meaningful health goal with acceptable risks?

Montana’s reporting requirements could help make experience with experimental care more visible. To be useful, reports must include people who did not improve, harms and patients lost to follow-up. Treatment records alone usually cannot show how much improvement came from the intervention rather than other care, expectations or the natural course of illness. Well-designed comparative studies remain essential. [18]

For someone considering a specific offer, the next step is to review its treatment evidence, current license, board decision, follow-up arrangements and financial terms with a clinician who is not selling it. The law opens a policy experiment. Its value for patients will be measured in the quality of care and the outcomes that follow.